{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:55:19Z","timestamp":1788317719073,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Polycythemia vera (PV) and essential thrombocythemia (ET) are diseases driven by canonical mutations in JAK2, CALR, or MPL gene. Previous studies revealed that in addition to driver mutations, patients with PV and ET can harbor other mutations in various genes, with no established impact on disease phenotype. We hypothesized that the molecular profile of patients with PV and ET is dynamic throughout the disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we performed a 37-gene targeted next-generation sequencing panel on the DNA samples collected from 49 study participants in two-time points, separated by 78-141 months. We identified 78 variants across 37 analyzed genes in the study population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>By analyzing the change in variant allele frequencies and revealing the acquisition of new mutations during the disease, we confirmed the dynamic nature of the molecular profile of patients with PV and ET. We found connections between specific variants with the development of secondary myelofibrosis, thrombotic events, and response to treatment. We confronted our results with existing conventional and mutation-enhanced prognostic systems, showing the limited utility of available prognostic tools.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The results of this study underline the significance of repeated molecular testing in patients with PV and ET and indicate the need for further research within this field to better understand the disease and improve available prognostic tools.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1224590","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T15:39:44Z","timestamp":1692632384000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease\u2019s phenotype"],"prefix":"10.3389","volume":"13","author":[{"given":"Patryk","family":"Sobieralski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Was\u0105g","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Leszczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"\u017buk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bieniaszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2014.113845","article-title":"Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms","volume":"102","author":"Grinfeld","year":"2017","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.exphem.2015.06.007","article-title":"Pathogenesis of myeloproliferative neoplasms","volume":"43","author":"Skoda","year":"2015","journal-title":"Exp Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/humu.24114","article-title":"A comprehensive bioinformatic analysis of 126 patients with an inherited platelet disorder to identify both sequence and copy number genetic variants","volume":"41","author":"Almazni","year":"2020","journal-title":"Hum Mutat"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3391","article-title":"Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity","volume":"34","author":"Chang","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2018.11.280","article-title":"Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia","volume":"124","author":"Wu","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3895","article-title":"DNMT3A in haematological Malignancies","volume":"15","author":"Yang","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01521-4","article-title":"Distinction of lymphoid and myeloid clonal hematopoiesis","volume":"27","author":"Niroula","year":"2021","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.637116","article-title":"Triple-negative essential thrombocythemia: clinical-pathological and molecular features","volume":"11","author":"Cattaneo","year":"2021","journal-title":"A Single-Center Cohort Study Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e00772","DOI":"10.1002\/mgg3.772","article-title":"TET2 missense variants in human neoplasia. A proposal of structural and functional classification","volume":"7","author":"Bussaglia","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2019.39.6.509","article-title":"Current aspects of clonal hematopoiesis: implications for clinical diagnosis","volume":"39","author":"Karner","year":"2019","journal-title":"Ann Lab Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0595-4","article-title":"DNA methylation disruption reshapes the hematopoietic differentiation landscape","volume":"52","author":"Izzo","year":"2020","journal-title":"Nat Genet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100587","article-title":"From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities","volume":"37","author":"Bewersdorf","year":"2019","journal-title":"Blood Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.284687","article-title":"Oligomerization of DNMT3A controls the mechanism of de novo DNA methylation","volume":"286","author":"Holz-Schietinger","year":"2011","journal-title":"J Biol Chem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2022.01.011","article-title":"JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis","volume":"211","author":"Soudet","year":"2022","journal-title":"Thromb Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281705","article-title":"lonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis","volume":"108","author":"Carr\u00e0","year":"2023","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006565","article-title":"Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA","volume":"6","author":"Garcia-Gisbert","year":"2022","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.045591","article-title":"Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: Analysis of molecular genetics and clinical phenotypes","volume":"96","author":"Stein","year":"2011","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.144","article-title":"The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration","volume":"24","author":"Abdel-Wahab","year":"2010","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0193-y","article-title":"Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid Malignancies using NGS","volume":"32","author":"Alberti","year":"2018","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0668-5","article-title":"Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis","volume":"34","author":"Bartels","year":"2020","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9026","article-title":"Bone marrow fibrosis in myelodysplastic syndromes: A prospective evaluation including mutational analysis","volume":"7","author":"Ramos","year":"2016","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am J Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14270","article-title":"Mutation status and burden can improve prognostic prediction of patients with lower-riskmyelodysplastic syndromes","volume":"111","author":"Jiang","year":"2020","journal-title":"Cancer Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ajh.25700","article-title":"Second cancers in MPN: Survival analysis from an international study","volume":"95","author":"Marchetti","year":"2020","journal-title":"Am J Hematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1224590\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T15:39:46Z","timestamp":1692632386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1224590\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":35,"alternative-id":["10.3389\/fonc.2023.1224590"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1224590","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"article-number":"1224590"}}